Long-Term Debt: Cyclacel Pharmaceuticals (BGMS)

Brandmark of Cyclacel (BGMS)

The current market quotes for Bio Green Med Solution Inc (BGMS) visualized below pertain to the defensive biotech sector, where returns are not tied to the economy but are based on successes in developing new drugs. The indicator stands at 0.00. Trials of innovative inhibitors against leukemias and interest from pharmaceutical behemoths are driving the stock's growth. Patents for selective tumor suppression ensure business stability, although profits depend on the test results.

BGMS (Cyclacel Pharmaceuticals) Company Long-Term Debt history from 09/13/2025 to 10/30/2026

Cyclacel Pharmaceuticals - analytical breakdowns and key metrics (BGMS)

- current quotes and average value forecast:
Stock Quotes cyclacel.com|BGMS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Bio Green Med Solution|BGMS - Total Company Value
- book capitalization data:
Net Assets per Single Share Bio Green Med Solution|BGMS - Company Book Value|Market-to-Book Ratio cyclacel.com|BGMS - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Bio Green Med Solution Inc|BGMS - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Cyclacel|BGMS - Company Total Debt|Debt to Net Assets Ratio Bio Green Med Solution|BGMS - Company Long-Term Liabilities|Amount of Current Liabilities Bio Green Med Solution|Quick Ratio cyclacel.com
- net income and valuation multiples indicators:
BGMS - Company Net Income
Fundamental company valuation:cyclacel.com
Core merchandise of Bio Green Med Solution

The long-term debt time series for Bio Green Med Solution Inc (BGMS) on GURU.Markets consolidates all strategic credit obligations, measuring the company's total debt load and its long-term capacity to service borrowings. Amidst a critical liquidity shortage for oncology research, this indicator allows for an assessment of insolvency risk and the extent of the biotech's reliance on emergency external financing.

Competitor analysis for Bio Green Med Solution Inc

GMAB - Company Long-Term Liabilities|EXEL - Company Long-Term Debt|Long-Term Debt Nuvalent Inc|Kymera Therapeutics Inc (KYMR) - Company Long-Term Debt|IDYA (IDEAYA Corp) - Company Long-Term Debt|Company Long-Term Debt Enliven Therapeutics|Long-Term Debt oricpharma.com ORIC|Company Long-Term Debts RLAY|Nurix Therapeutics Inc (NRIX) - Long-Term Indebtedness|Tyra Bio - Company Long-Term Liabilities|Verastem Corp (VSTM) - Long-Term Debt|GLUE: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings CGEM (cullinanoncology.com)|IMRX (Immuneering) - Company Long-Term Liabilities|CCCC: Amount of Long-Term Liabilities|BDTX (Black Diamond Therapeutics Inc.) - Company Long-Term Debts|Company Long-Term Debts Repare Therapeutics Inc|Company Long-Term Debt PMV Pharmaceuticals (PMVP)|KPTI (karyopharm.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts PPCB (Propanc Biopharma)|Long-Term Indebtedness Aadi Bioscience Inc|Aileron - Company Long-Term Debts|Long-Term Debt Blueprint Medicines|GLYC (glycomimetics.com) - Company Long-Term Liabilities|SWTX: Amount of Long-Term Liabilities